Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease
Clifford R. Jack(Mayo Clinic), Norman L. Foster(University of Utah), Nick C. Fox(NIHR Queen Square Dementia Biomedical Research Unit), Philip Scheltens(Amsterdam University Medical Centers), Marc Cantillon(Critical Path Institute), Jean‐François Mangin(Centre National de la Recherche Scientifique), Harald Hampel(Sorbonne Université), Joyce Suhy(BioClinica (United States)), Giovanni B. Frisoni(University of Geneva), Frederik Barkhof(National Hospital for Neurology and Neurosurgery), Charles DeCarli(University of California, Davis), Adam J. Schwarz(Eli Lilly (United States)), Matt A. Bernstein(University of London), Keith A. Johnson(Brigham and Women's Hospital), Paul M. Thompson(University of Southern California), David Hill(Guy's Hospital), Michael W. Weiner(University of California, San Francisco), Patricia E. Cole(Takeda (United States)), Reisa A. Sperling(Harvard University), Bruno Dubois(Portland State University), Simon Duchesne(Université Laval)
Cited by 220
Related Papers
The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|18.9k
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|7.1k
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration
|The Lancet Neurology|2013|5.4k